Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy  Paller; Andrew  Blauvelt; Weily Soong; Shinichi Imafuku; Chih-ho Hong; Marie  Schuttelaar; Petra Amoudruz; Azra Kurbasic; Lise Soldbro; Katja Lophaven; Michael Cork; Anthony  Bewley; Eric Simpson

doi:10.25251/skin.6.supp.s29

Amy Paller

Northwestern University Feinberg School of Medicine

Andrew Blauvelt

Oregon Medical Research Center, Portland, OR, USA

Weily Soong

Allervie Health-Alabama Allergy & Asthma Center

Shinichi Imafuku

Fukuoka University Hospital, Fukuoka, Japan

Chih-ho Hong

University of British Columbia

Marie Schuttelaar

University Medical Centre Groningen

Petra Amoudruz

LEO Pharma A/S, Ballerup, Denmark

Azra Kurbasic

LEO Pharma A/S, Ballerup, Denmark

Lise Soldbro

LEO Pharma A/S, Ballerup, Denmark

Katja Lophaven

LEO Pharma A/S, Ballerup, Denmark

Michael Cork

University of Sheffield

Anthony Bewley

Barts Health NHS Trust

Eric Simpson

Oregon Medical Research Center, Portland, OR, USA

Keywords

atopic dermatitis

Abstract

N/A

References

1. Marciniak J. Acta Derm Venereol. 2017;97(6):711–714. doi: 10.2340/00015555-2633.

2. Ricci G. Dermatol Reports.
2011;4(1):e1. doi: 10.4081/dr.2012.e1.

3. Slattery M. J Allergy Clin Immunol. 2011; 128(3):668–671.e3. doi:
10.1016/j.jaci.2011.05.003.

4. Halvorsen J. J Invest Dermatol. 2014;134(7):1847–1854. doi: 10.1038/jid.2014.70.

5. Bieber T.
Allergy. 2020;75(1):54-62. doi: 10.1111/all.13954.

6. Furue K et al. Immunology. 2019; 158(4): 281-286. doi: 10.1111/imm.13120.

7. Szegedi K et al. JEADV. 2015;29(11):2136–2144. doi: 10.1111/jdv.13160.

8. Tsoi LC et al. J Invest Dermatol.
2019;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018.

9. Popovic B et al. J Mol Biol. 2017; 429(2): 208–219. doi:

10.1016/j.jmb.2016.12.005. 10. Wollenberg A. Br J Dermatol. 2021; 184(3):437–449. doi: 10.1111/bjd.19574.

Poster PDF

Published

Mar 4, 2022

DOI https://doi.org/10.25251/skin.6.supp.s29

How to Cite

Paller, A. ., Blauvelt, A. ., Soong, W., Imafuku, S., Hong, C.- ho, Schuttelaar, M. ., Amoudruz, P., Kurbasic, A., Soldbro, L., Lophaven, K., Cork, M., Bewley, A. ., & Simpson, E. (2022). Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine, 6(2), s29. https://doi.org/10.25251/skin.6.supp.s29

Issue

Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

Section

Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt, Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan, Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Andrew Blauvelt, Steven Kempers, Seth Forman, Edward Lain, Suzanne Bruce, Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Philip Brown, Leon Kircik, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, Melinda Gooderham, Kim Papp, Laura Ferris, Mark Lebwohl, David Adam, Javier Alonso-Llamazares, Chih-ho Hong, Steve Kempers, Leon Kircik, Wei Jing Loo, Daniel Stewart, Walter Nahm, Matthew Zirwas, Patrick Burnett, Robert Higham, Lynn Navale, David Berk, Long-term Safety and Efficacy of Roflumilast Cream 0.3% in Adult Patients With Chronic Plaque Psoriasis: Results From a 52-Week, Phase 2b Open-Label Study , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Leon Kircik, Philip Brown, Anna Tallman, Mark Lebwohl, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley, Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2 , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Phoebe Rich, Howard Sofen, Jo Lambert, Joe Merola, Mark Lebwohl, Lauren Hippeli, Renata Kisa, Subhashis Banerjee, Alexa Kimball, Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue
Javier Alonso-Llamazares, Melinda Gooderham, Jerry Bagel, John Browning, Zoe Draelos, Kimberly Grande, Adelaide Herbert, Wei Jing Loo, Chih-ho Hong, Mark Lebwohl, Walter Nahm, Kim Papp, David Pariser, Jennifer Soung, Linda Stein Gold, Irina Turchin, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)